Zanubrutinib
Zanubrutinib
Zanubrutinib (pronounced as zan-u-bru-ti-nib) is a small molecule inhibitor specifically designed to target the Bruton's tyrosine kinase (BTK), a crucial enzyme in the B-cell receptor signaling pathway. This drug is used in the treatment of B-cell malignancies.
Etymology
The name 'Zanubrutinib' is derived from the drug's function. 'Zanu' is a prefix used in pharmaceutical nomenclature for drugs that inhibit kinases, 'brut' refers to Bruton's tyrosine kinase, the target of the drug, and 'nib' is a suffix used for kinase inhibitors.
Usage
Zanubrutinib is used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is also used in the treatment of Waldenström's macroglobulinemia, a rare type of non-Hodgkin's lymphoma.
Mechanism of Action
Zanubrutinib works by inhibiting the Bruton's tyrosine kinase (BTK), an enzyme that plays a crucial role in the development and functioning of various immune cells including B-lymphocytes. By blocking BTK, zanubrutinib helps to kill and reduce the number of cancer cells, thereby slowing down the progression of the disease.
Related Terms
- Bruton's tyrosine kinase
- B-cell receptor
- B-cell malignancies
- Mantle cell lymphoma
- Waldenström's macroglobulinemia
External links
- Medical encyclopedia article on Zanubrutinib
- Wikipedia's article - Zanubrutinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski